Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment

MET exon 14 mutation is a defined distinct molecular subset of NSCLC. This rare mutation presents in 3% of patients with NSCLC.1 Crizotinib has proved to be highly effective in patients with advanced NSCLC with MET exon 14 skipping mutation.2 Here, we report the case of a patient with lung adenocarcinoma with novel MET 14 skipping who benefited from crizotinib.